Choice of insurer is an essential precondition for efficiency in healthcare systems based on regulated competition. However, supplementary insurance (SI) may restrict choice of insurer for basic health insurance (BI) due to a joint purchase of BI and SI. Roos and Schut (Eur J Health Econ 13(1):51-62, 2012) found that the belief in not being accepted by another insurer for SI was an important reason for not switching insurer for BI for 4% of the non-switching Dutch population in 2006. This increased to approximately 7% in 2009. In this paper, we provide evidence that in 2011 and 2012 approximately 10% of the Dutch population expected that another insurer would not accept them for SI. An additional 20% of the consumers expected to be accepted by another insurer, but only for a higher premium than other consumers with the same SI. About one-third of the elderly (55+) consumers, and more than half of the consumers with bad or moderate health status, expected their current insurer to offer them more favourable conditions for SI, in terms of acceptance and premium, than other insurers do for similar SI. However, if dissatisfied high-risk consumers, due to a joint purchase of BI and SI, do not switch insurer for BI, the disciplining effect of 'voting with one's feet' is substantially reduced. This is a serious problem that may increase in coming years. We discuss several potential solutions. Our conclusion is that the integration of BI and SI into one basic-plus-insurance is an effective solution under current EU legislation. This conclusion may also be relevant for other countries.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s10198-013-0519-7 | DOI Listing |
J Manag Care Spec Pharm
January 2025
The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, Department of Pharmacy, University of Washington, Seattle.
Background: The introduction of cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6is) has transformed the treatment landscape for patients with hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer (MBC). To our knowledge, no studies have quantified health care resource utilization (HRU) or economic burden following CDK4/6i initiation in the Medicare population.
Objective: To describe HRU and quantify health care costs among Medicare-enrolled patients with HR+ HER2- MBC treated with CDK4/6is in the first-line setting.
Ann Otol Rhinol Laryngol
January 2025
University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Background: Granulation tissue formation and tracheitis are common pediatric tracheostomy complications. Ciprofloxacin/dexamethasone is frequently prescribed, but the influence of social determinants on this topic is unexplored.
Methods: This study extends a prior cohort study of pediatric tracheostomy patients at a single academic institution from 2016 to 2020.
Aust Occup Ther J
February 2025
School of Primary and Allied Health Care, Monash University, Peninsula Campus, Frankson, VIC, Australia.
J Neural Transm (Vienna)
December 2024
IAB - Interdiciplinary Working Group for Movement Disorders, Hamburg, Germany.
Botulinum toxin (BT) therapy is the therapy of choice for most forms of dystonia. We want to describe its costs, if all dystonia patients in Germany would have access to optimal BT therapy. For this, we combined the latest data on epidemiology of dystonia and dosing of BT therapy for dystonia.
View Article and Find Full Text PDFPLoS One
December 2024
A.J. Drexel Autism Institute, Drexel University, Philadelphia, PA, United States of America.
The objective of this study was to identify utilization of housing support provided by the U.S. Department of Housing and Urban Development (HUD) among autistic people in the U.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!